Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen

Actuate Therapeutics (NASDAQ:ACTU) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Actuate Therapeutics Stock Down 10.6%

Actuate Therapeutics stock opened at $2.86 on Friday. The business has a 50 day moving average price of $4.88 and a two-hundred day moving average price of $6.35. Actuate Therapeutics has a 12 month low of $2.73 and a 12 month high of $11.99. The stock has a market cap of $66.47 million, a price-to-earnings ratio of -3.29 and a beta of 0.10.

Insiders Place Their Bets

In other news, Director Todd S. Thomson sold 280,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $5.80, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 904,795 shares in the company, valued at $5,247,811. This represents a 23.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 69.34% of the company’s stock.

Institutional Investors Weigh In On Actuate Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ACTU. Voss Capital LP grew its holdings in shares of Actuate Therapeutics by 213.2% in the 3rd quarter. Voss Capital LP now owns 896,278 shares of the company’s stock valued at $5,996,000 after acquiring an additional 610,138 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new stake in Actuate Therapeutics during the fourth quarter worth about $579,000. BIOS Capital Management LP boosted its position in Actuate Therapeutics by 0.9% during the third quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after purchasing an additional 84,917 shares during the last quarter. Geode Capital Management LLC boosted its position in Actuate Therapeutics by 252.5% during the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after purchasing an additional 84,561 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after purchasing an additional 51,546 shares in the last quarter.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.